Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

11.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report.

Leukemia·2026
Same author

Unplanned Excision and the Race to Cure Sarcomas: Commentary on an article by Jacob Jahn, BS, et al.: "Effect of Timing of First Consultation with a Sarcoma Specialist Following Unplanned Excision. Oncologic Outcomes of Patients with Soft-Tissue Sarcomas".

The Journal of bone and joint surgery. American volume·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same author

Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML.

Blood·2026
Same author

Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis.

Blood·2026
Same author

Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results.

Cancer discovery·2026

相关实验视频

Updated: Jun 2, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.4K

进化压力 形状 不差异化的形肉瘤 发育和放射治疗反应

Erik S Blomain1, Shaghayegh Soudi2, Ziwei Wang2

  • 1Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.

Cancer research
|January 14, 2025
PubMed
概括

放射治疗通过扩大耐药子克隆来驱动癌症的进化. 针对这些耐药癌细胞,特别是那些涉及信号的癌细胞,可以提高治疗的有效性.

更多相关视频

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

相关实验视频

Last Updated: Jun 2, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.4K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

科学领域:

  • 在瘤学瘤学.
  • 癌症基因组学 癌症基因组学
  • 进化生物学 进化生物学

背景情况:

  • 放射治疗是癌症治疗的基石,约有50%的患者使用.
  • 了解辐射如何影响瘤进化对于改善治疗结果至关重要.
  • 系统疗法可以选择耐药瘤亚群,强调需要研究辐射的影响.

研究的目的:

  • 在瘤发生过程中和对放射治疗的反应中研究未分化的多形瘤 (UPS) 的进化动态.
  • 识别放射电阻的机制和潜在的治疗点.
  • 评估循环瘤DNA (ctDNA) 对监测瘤演变的有用性.

主要方法:

  • 从20名UPS患者中120个瘤区域的综合时间基因组分析.
  • 循环瘤DNA (ctDNA) 的纵向分析.
  • 计算进化生物学管道的应用.

主要成果:

  • 无辐射UPS瘤显示线性进化,随后是分支进化,具有明显的突变过程.
  • 放射治疗显著增加了选择压力,改变了亚克隆丰度.
  • 抑制载体使瘤细胞对辐射敏感,亚克隆收缩与信号改变有关.
  • ctDNA分析准确地监测了非侵入性的亚克隆变化.

结论:

  • 辐射对UPS施加了显著的选择性压力,促进了抗性亚克隆的扩张.
  • 向耐辐射子克隆,特别是与信号通路相关的子克隆,可能会提高放射治疗的疗效.
  • 使用ctDNA进行瘤演变的非侵入性监测是可行的,并且对治疗评估有价值.